NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Intensity Therapeutics, Inc. (INTS) Stock Analysis

Intensity Therapeutics, Inc. (INTS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

INTS

$3.14

−$0.14 (−4.19%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare INTS with… →

INTS Key Statistics

As of Oct 21, 2026
Trading
Open
$3.22
Previous Close
$3.28
Day's Range
3.13–3.51
52-Week Range
3.10–43.50
Volume
9.81K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
3.08
Valuation
Market Cap
$10.26M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.89
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$11.61M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
3.26M
1-Year Return
−50.90%
Dividend and dates
Avg Volume
26.20K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, INTS closed at $3.14, −50.90% over 1 year.

Intensity Therapeutics, Inc. (INTS) has a market capitalization of $10.26M.

In fiscal 2025, INTS reported revenue of $0.00.

INTS Stock Return by Calendar Year

Intensity Therapeutics, Inc. (INTS) return since Jun 2023: what $10,000 became

1 year
$10,000 $4,910
−50.90%
3 years
$10,000 $416
−95.84%
Since Jun 2023
$10,000 $211
−97.89%

If you had invested $10,000 in Intensity Therapeutics, Inc. (INTS) at the close on June 30, 2023, the earliest close on record here, it would have been worth $211 at the close on October 21, 2026: −97.89% in total, −68.83% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−69.34%
2025−76.70%
2024−79.46%
2023 (partial year)+43.79%

As of October 21, 2026.

INTS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$11.61M—
2024$0.00−$16.27M—
2023$0.00−$10.54M—
2022$0.00−$7.58M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$11.97M−$11.61M—
2024$0.00—−$16.59M−$16.27M—
2023$0.00—−$8.32M−$10.54M—
2022$0.00—−$7.55M−$7.58M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Intensity Therapeutics, Inc. (INTS) is capitalised at $10.26M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 5 employees.

INTS last closed at $3.14 on October 21, 2026. That is −$0.14 (−4.19%) against the previous close. The 52-week range on file runs from $3.10 to $43.50. The latest close sits 1.47% above that 52-week low.

Financial Health

In fiscal 2025, Intensity Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $11.61M. Trailing earnings per share are −3.89.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year total return is −50.90%. Measured over 3 years, that is −65.34% a year compounded. Beta against the wider market is reported at 3.08. Annualized volatility over the trailing 3 years is 254.17%.

Growth & Income

The record shows no dividend for INTS.

The strongest complete calendar year on file is 2025 at −76.70%; the weakest is 2024 at −79.46%. 2026 is still running; the total return is −69.34% year to date.

Peer Comparison

Intensity Therapeutics, Inc. (INTS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Intensity Therapeutics, Inc. INTS $10.26M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Intensity Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Visit website →